EMA's PRAC defensive over industry criticism but accepts improvements needed
This article was originally published in SRA
Executive Summary
Every time the European Medicines Agency publishes details of meetings organized by its new Pharmacovigilance Risk Assessment Committee, these are anxiously scanned by drug companies keen to know whether any of their products are affected by the agency's signal detection and management programme.